In order to counter such stigma and discrimination, women living with HIV and Hepatitis B came together at The Voice of ...
This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
Note: ViiV’s announcement can be read on their site at ...
UNAIDS supports the UN Office for the High Commissioner of Human Rights' statement that these laws will “impose discriminatory restrictions on education, public discussion, and gatherings related to ...
This document is designed as a summary and visual aid of the steps and recommendations for strengthening sustainable youth-led HIV responses included in Youth Next Level: guidance to strengthen ...
GENEVA, 8 October 2024—Responding to ViiV’s announcement on long-acting cabotegravir , UNAIDS Executive Director Winnie Byanyima said: “New HIV prevention medication, in the form of a long-acting ...
GENEVA, 1 October 2024—UNAIDS expresses deep concern over the recently adopted anti-LGBTQ+ legislation in Georgia, which poses serious risks to public health and human rights. UNAIDS supports the UN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback